Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure

被引：0
|
作者：
Gupta, A. [1 ]
Laheru, D. [1 ]
机构：
[1] Johns Hopkins Med, Sidney Kimmel Comprehens Canc Ctr, Med Oncol, Baltimore, MD USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2627
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1680P
引用
收藏
页码：S921 / S921
页数：1
相关论文
共 50 条
  • [31] A real-world study comparing apatinib combined with irinotecan versus irinotecan as second-line or above therapy in patients with advanced or metastatic gastric cancer
    Nie, C.
    Lv, H.
    Chen, B.
    Xu, W.
    Wang, J.
    Wang, S.
    Liu, Y.
    He, Y.
    Zhao, J.
    Chen, X.
    ANNALS OF ONCOLOGY, 2022, 33 : S1474 - S1474
  • [32] Trends in real-world clinical outcomes among patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) treated with liposomal irinotecan based regimens in the United States (US).
    Koeller, Jim M.
    Cockrum, Paul
    Belanger, Bruce
    Corvino, Frank A.
    Surinach, Andy
    Kim, George P.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Real-world progression outcomes among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States
    Kim, G.
    Cockrum, P.
    Surinach, A.
    Wang, S.
    Lamarre, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S1092 - S1093
  • [34] A phase 1 study of liposomal irinotecan in patients with advanced breast cancer
    Fan, Ying
    Zhang, Qingyuan
    Yan, Min
    Qu, Xiujuan
    Yin, Yongmei
    Sun, Tao
    Yang, Jin
    Wang, Ying
    Wang, Xu
    Niu, Zhaofeng
    Wang, Xinshuai
    Sun, Sanyuan
    Zhao, Weihong
    Liu, Yanping
    Miao, Niu
    Zhao Xuemin
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Survival predictors in pancreatic cancer patients on liposomal irinotecan plus fluorouracil/leucovorin: A multicenter observational study
    Keum, J.
    Lee, H. S.
    Park, C. S.
    Kim, J.
    Jang, W.
    Shin, K. I.
    Kang, H.
    Lee, S. H.
    Jo, J. H.
    Jang, S-I.
    Chung, M. J.
    Park, J. Y.
    Park, S. W.
    Cho, J. H.
    Bang, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S143 - S143
  • [36] Angiotensin system inhibitors improve survival in patients undergoing pancreatic cancer resection: a meta-analysis of real-world evidence
    Lin, Yuxuan
    Liao, Yonghe
    Shen, Jinhai
    EXPERT REVIEW OF ANTICANCER THERAPY, 2025,
  • [37] Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicenter observational study
    Keum, Jiyoung
    Lee, Hee Seung
    Park, Chan Su
    Kim, Jeehoon
    Jang, Wonjoon
    Shin, Kyung In
    Kang, Huapyong
    Lee, Sang Hoon
    Jo, Jung Hyun
    Jang, Sung Ill
    Chung, Moon Jae
    Park, Jeong Youp
    Park, Seung Woo
    Cho, Jae Hee
    Bang, Seungmin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [38] Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
    Chen, Li-Tzong
    Macarulla, Teresa
    Blanc, Jean-Frederic
    Mirakhur, Beloo
    de Jong, Floris A.
    Belanger, Bruce
    Bekaii-Saab, Tanios
    Siveke, Jens T.
    CANCERS, 2019, 11 (08)
  • [39] Irinotecan liposome-based regimen in Chinese patients with advanced pancreatic cancer: A prospective, multi-center, observational real-world study
    Xu, J.
    Jiang, K.
    Lu, H.
    Gong, X.
    Li, H.
    Wu, Y.
    Chen, L.
    Liu, W.
    Wu, D.
    Du, J.
    Sun, L.
    Zhao, Y.
    Dai, E.
    An, H.
    Liu, Y.
    Wang, X.
    Liu, Q.
    Yu, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S1500 - S1500
  • [40] Real-world use of liposomal irinotecan-based regimens among patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) in the United States (US).
    Kim, George P.
    Cockrum, Paul
    Surinach, Andy
    Koeller, Jim M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345